Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons.
The announcement and publication of the second National Acute Spinal Cord Injury Study (NASCIS II) project's findings regarding the role of high dose methylprednisolone in improving neurological outcomes following acute traumatic spinal cord injury generated widespread excitement and interest. To determine the association between this interest and actual use and implementation of the protocol, Colorado's comprehensive population-based spinal cord injury surveillance data were examined. The medical records of 218 SCI survivors injured between May 1, 1990 and December 31, 1991, and of 145 persons spinal cord injured 2 years later, during 1993, were reviewed to determine the rapidity and extent of NASCIS II implementation by Colorado's hospitals, factors associated with use and non-use of the protocol, changing usage trends over time, and the short term neurological outcomes of patients who received the protocol. Clear documentation of the protocol's usage was present for only 46% of the reported patients' medical records in 1990-91, and 61% in 1993. Small, emergency triage facilities were significantly more likely to use the protocol than larger acute care hospitals, and patients with initially incomplete injuries were less likely to receive the drug. There were no significant differences in neurological outcomes, using the Frankel classification system, between those who received the protocol and those who did not. The limitations and implications of these findings are discussed.
Gerhart
K A
KA
Craig Hospital, Rocky Mountain Regional Spinal Injury System, Englewood, Colorado, USA.
Johnson
R L
RL
Menconi
J
J
Hoffman
R E
RE
Lammertse
D P
DP
D006801:Humans; D008137:Longitudinal Studies; D008499:Medical Records; D008775:Methylprednisolone / Q000627:therapeutic use*; D011159:Population Surveillance; D012189:Retrospective Studies; D013119:Spinal Cord Injuries / Q000188:drug therapy*; D016896:Treatment Outcome
D008775:Methylprednisolone